Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse

William Stephen Brimijoin, Xiaoyun Shen, Frank Orson, Thomas Kosten

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.

Original languageEnglish (US)
Pages (from-to)323-332
Number of pages10
JournalExpert Review of Vaccines
Volume12
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Active Immunotherapy
Cocaine
Substance-Related Disorders
Vaccines
Cocaine-Related Disorders
Street Drugs
Nicotine
Reward
Pharmaceutical Preparations
Genes
Monoclonal Antibodies
Clinical Trials
Technology
Safety
Recurrence
Antibodies
Enzymes
Therapeutics
Transfer (Psychology)

Keywords

  • adenovirus gene transfer vector
  • antidrug immunoglobulin
  • butyrylcholinesterase
  • clinical trial
  • cocaine abuse
  • cocaine hydrolase
  • metabolism-based therapies
  • monoclonal antibody
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. / Brimijoin, William Stephen; Shen, Xiaoyun; Orson, Frank; Kosten, Thomas.

In: Expert Review of Vaccines, Vol. 12, No. 3, 03.2013, p. 323-332.

Research output: Contribution to journalArticle

@article{cdcb1e6b283f42bebdc6b51958780022,
title = "Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse",
abstract = "This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.",
keywords = "adenovirus gene transfer vector, antidrug immunoglobulin, butyrylcholinesterase, clinical trial, cocaine abuse, cocaine hydrolase, metabolism-based therapies, monoclonal antibody, vaccine",
author = "Brimijoin, {William Stephen} and Xiaoyun Shen and Frank Orson and Thomas Kosten",
year = "2013",
month = "3",
doi = "10.1586/erv.13.1",
language = "English (US)",
volume = "12",
pages = "323--332",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse

AU - Brimijoin, William Stephen

AU - Shen, Xiaoyun

AU - Orson, Frank

AU - Kosten, Thomas

PY - 2013/3

Y1 - 2013/3

N2 - This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.

AB - This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.

KW - adenovirus gene transfer vector

KW - antidrug immunoglobulin

KW - butyrylcholinesterase

KW - clinical trial

KW - cocaine abuse

KW - cocaine hydrolase

KW - metabolism-based therapies

KW - monoclonal antibody

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84875130963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875130963&partnerID=8YFLogxK

U2 - 10.1586/erv.13.1

DO - 10.1586/erv.13.1

M3 - Article

C2 - 23496671

AN - SCOPUS:84875130963

VL - 12

SP - 323

EP - 332

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 3

ER -